Episode 455: ESMO 2025 Urothelial Cancer...

In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide. 

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions. 

This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent studies, controversies, and future directions in GU oncology. 

<p>Today’s episode is focusing on bladder cancer - what you need to know about the pathology, presentation, diagnostic work-up, staging, treatment, and rarer upper GU tract presentations.</p> 

In this episode, we review the high-yield topic of Bladder Cancer from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets 

<p>This episode covers bladder cancer.<br/><br/>Written notes can be found at <a href='https://zerotofinals.com/surgery/urology/bladdercancer/'>https://zerotofinals.com/surgery/urology/bladdercancer/</a> or in the urology section of the Zero to Finals surgery book.</p><p>The audi ... Show More

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ... Show More

<p>Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ... Show More

<p>We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.</p> 

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ... Show More